To cite this paper use one of the standards below:
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, with no current cure or effective treatment that could slow down their progression. Leading the search for new therapeutic alternatives, peptides have become a common theme for many scientists, due to their unique properties, with many of them showing promising efficacy.
Fraternine-10 and Octovespin are two examples of bioinspired peptides that showed promising results in AD and PD animal models but their mechanism of action is still under study. In vitro research plays a crucial role in the early stages of drug development, allowing for a safe and precise way to evaluate a compound's therapeutic potential, thus, for Fratenine-10 and Octovespin, in vitro studies could provide a controlled environment to assess their pathophysiological relevance on cellular models that replicate neurodegeneration scenarios, which is the aim of this study.
Therefore, to evaluate Octovespin and Fraternine-10 neuroprotection property, human neuroblastoma (SHSY-5Y) was used and 6-OHDA was added to induce neurotoxicity, followed by measurements of DCFDA and Resazurin fluorescence, to evaluate ROS production and cell viability, respectively. To evaluate the peptide's neurotoxicity, human neuroblastoma (SHSY-5Y) was incubated with Fraternine and Octovespin at similar doses. At last the hemolytic activity of both peptides was evaluated in a 3% suspension of erythrocytes from mice blood, analyzed using spectrophotometry.
When peptides were added in neuroblastoma cells exposed to 6-OHDA there was no change on the resazurin fluorescence, implying that Fraternine-10 and Octovespin were not able to prevent 6-OHDA neurotoxicity. However, when peptides were incubated with neuroblastoma cells alone, a decreased level of fluorescence was observed at the DCFDA trials without changes in resazurin. Hemolysis assays revealed that none of the peptide doses caused hemolysis.
In conclusion, the results from the neurotoxicity assay using resazurin showed that the peptides at the tested doses were not neuroprotective, but had an antioxidant activity. Moreover, the hemolytic assay showed that both peptides, in the tested doses, were not hemolytic for the erythrocytes from mice. Taken together, more studies and optimization of those peptides are necessary in order to elucidate better their effect.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper